10.05.2021 Carl Zeiss Meditec AG  DE0005313704

DGAP-News: Carl Zeiss Meditec returns to significant revenue growth in H1 2020/21


 

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Half Year Report/Half Year Results
Carl Zeiss Meditec returns to significant revenue growth in H1 2020/21

10.05.2021 / 07:00
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec returns to significant revenue growth in H1 2020/21
 
Strong increase in operating profit due to low costs
 

JENA, 10 May 2021

Carl Zeiss Meditec generated revenue of €767.4m in the first six months of fiscal year 2020/21 (prior year: €714.9m), an increase of +7.3% (adjusted for currency effects: +10.5%). Earnings before interest and taxes (EBIT) increased to €162.7m (prior year: €102.5m). The EBIT margin was 21.2% (prior year: 14.3%).

"We are very satisfied with the results for the first six months - all regions contributed to our return to roughly the same growth rate as prior to the COVID-19 pandemic. The impact from the pandemic is gradually fading," said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

Strong performance in SBU Ophthalmic Devices

Revenue in the strategic business unit (SBU) Ophthalmic Devices increased by +14.0% in the first six months of fiscal year 2020/21 (adjusted for currency effects: +17.2%) to €590.1m (prior year: €517.7m). Recurring revenue from consumables, implants and services contributed significantly to growth. Revenue in the Microsurgery SBU decreased by -10.1% (adjusted for currency effects: -7.0%) to €177.3m (prior year: €197.2m). Orders received in the SBU Microsurgery were already back on a positive trend.

All reporting regions contribute to growth

Revenue in the EMEA[1] region increased by +3.8% (adjusted for currency effects: +5.4%) to €216.7m (prior year: €208.7m). There was a positive trend in the markets of Germany, France and Southern Europe, and the UK.

The Americas region grew by +3.0% after adjustment for currency effects - in the reporting currency, revenue decreased by -4.1% to €197.2m (prior year: €205.5m). The USA gave a solid performance, while the markets of Latin America lagged behind the prior year.

In the APAC[2] region, revenue increased significantly year-on-year from €300.7m to €353.5m (+17.6%; adjusted for currency effects: +19.2%). Once again, the strongest contributions to growth were generated in China and South Korea, which also benefited from base effects due to the COVID-19 pandemic in the prior year. By contrast, the Japanese and Indian markets continued to lag behind the prior year.

Operating result up significantly year-on-year

The operating result (earnings before interest and taxes: EBIT) increased to €162.7m in the first six months of fiscal year 2020/21 (prior year: €102.5m). Low selling and marketing expenses, in particular, contributed to this. EBIT also includes positive one-time income of €2.4m from the sale of a property, as already reported in the first quarter of 2020/21. The EBIT margin increased to 21.2% (prior year: 14.3%). Adjusted for special effects, this amounted to 21.4% (prior year: 14.7%). Earnings per share increased to €1.12 (prior year: €0.71).

Carl Zeiss Meditec anticipates a further normalization of business over the further course of fiscal year 2020/21. This expectation is based on the assumption that there will not be another global deterioration of the pandemic situation.

Revenue is expected to increase to around €1.6b in fiscal year 2020/21 (prior year: €1,335.5m). The EBIT margin is expected to rise to around 20% in fiscal year 2020/21 (prior year: 13.3%), bolstered to a great extent by the currently low selling and marketing expenses. In the medium term, the Company still expects to achieve an EBIT margin that is sustainably above 18%.

Revenue by strategic business unit

All figures in €m 6 months 2020/21  6 months 2019/20  Change from previous year  Change from prior year 
(currency-adjusted)
Ophthalmic Devices 590.1 517.7 +14.0% +17.2%
Microsurgery 177.3 197.2 -10.1% -7.0%
Overall group 767.4 714.9 +7.3% +10.5%
 

Revenue by region

All figures in €m  6 months 2020/21  6 months 2019/20  Change from prior year  Change from prior year 
(currency-adjusted)
EMEA 216.7 208.7 +3.8% +5.4%
Americas 197.2 205.5 -4.1% +3.0%
APAC 353.5 300.7 +17.6% +19.2%
Overall group 767.4 714.9 +7.3% +10.5%
 

 

Further information on our publication and the Analyst Conference Call on the results for the first six months of fiscal year 2020/21 can be found at
https://www.zeiss.com/meditec-ag/investor-relations/financial-calendar/conference-calls.html

 

 

Contact for investors and press

Sebastian Frericks
Director Investor Relations, Carl Zeiss Meditec AG
Phone: + 49 (0)3641 220-116
Email: [email protected]

www.zeiss.de/presse

[1] Europe, Middle East, Africa
[2] Asia/Pacific



10.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected]
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1194235

 
End of News DGAP News Service

1194235  10.05.2021 

fncls.ssp?fn=show_t_gif&application_id=1194235&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 1.088,37 1.189,90 1.280,86 1.459,32 1.335,45 1.646,79 1.710,00
EBITDA1,2 174,56 205,07 228,41 313,03 237,98 435,20 407,50
EBITDA-Marge3 16,04 17,23 17,83 21,45 17,82 26,43 23,83
EBIT1,4 154,33 180,83 197,13 264,66 177,55 373,61 344,00
EBIT-Marge5 14,18 15,20 15,39 18,14 13,30 22,69 20,12
Jahresüberschuss1 99,97 135,78 126,23 160,58 123,42 237,52 221,00
Netto-Marge6 9,19 11,41 9,86 11,00 9,24 14,42 12,92
Cashflow1,7 111,77 37,73 187,21 219,63 178,53 362,66 0,00
Ergebnis je Aktie8 1,21 1,57 1,41 1,79 1,37 2,64 2,42
Dividende8 0,42 0,55 0,55 0,65 0,50 0,90 0,90
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

XETR:AFX Charts by TradingView (c)


INVESTOR-INFORMATIONEN
©boersengefluester.de
Carl Zeiss Meditec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
531370 142,250 Halten 12.722,92
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
45,16 31,92 1,46 93,28
KBV KCV KUV EV/EBITDA
8,06 35,08 7,73 27,08
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,50 0,90 0,63 30.03.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.02.2022 13.05.2022 05.08.2022 10.12.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-18,68% -16,17% -23,05% 12,01%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Carl Zeiss Meditec AG  ISIN: DE0005313704 können Sie bei DGAP abrufen


Medtech , 531370 , AFX , XETR:AFX